In contrast to prior studies, adding bevacizumab to erlotinib provides no progression-free survival benefit for treatment-naive patients.
A machine learning technique was noninferior to traditional immunohistochemistry in predicting molecular biomarker expression.
Proton-pump inhibitors did not reduce upper gastrointestinal bleeding in patients with stable cardiovascular disease.
Outcomes were superior with nab-paclitaxel versus sb-paclitaxel.
When anticoagulation is stopped after initial treatment, cumulative incidence of recurrent VTE is 10%, 16%, 25%, and 36% at 1, 2, 5, and 10 years, respectively.
Incidental increases in platelet counts and hematocrit values were associated with ischemic stroke and myocardial infarction, respectively.
Hormonal therapies are associated with higher risk for disease activity.
Incidence of herpes zoster infection was significantly reduced with adjuvanted recombinant zoster vaccine versus placebo in a high-risk immunosuppressed group.
In previously treated patients with FGFR alterations, the response rate with erdafitinib was 40%.
CRC risk associated with nonadvanced adenomas or small serrated polyps is no different than having no polyps.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.